33257 Secukinumab effects on cardiovascular risk factors in patients with psoriasis, psoriatic arthritis and axial spondyloarthritis: Results from post hoc analyses of pooled data from 19 phase 3/4 clinical studies

Abstract

Psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) are chronic systemic inflammatory disorders closely associated with cardiovascular (CV) disease. Here, we evaluated the effect of secukinumab on CV risk parameters in 9197 patients included in a post hoc analysis of 19 pooled phase 3/4 secukinumab studies in PsO (n = 4742), PsA (n = 2475), and AxSpA (n = 1980). Traditional (body mass index [BMI], fasting glucose, blood pressure, cholesterol, and lipids) and inflammatory CV risk parameters (high-sensitivity C-reactive protein [hsCRP] and neutrophil-lymphocyte ratio [NLR]) were assessed.